Cyrille Tupin, Chief executive officer of Abionyx Pharma, a new generation biotechnology company, spoke at the press conference to present the results of the Racers clinical study, which evaluates the efficacy of the new drug Cer-001 in the treatment of septic patients with high risk of developing acute kidney injury (Aki).
#Cyrille #Tupin #Encouraging #results #Cer001 #studio #Racers